TLSA vs TPST

Tiziana Life Sciences Ltd vs Tempest Therapeutics, Inc. — Valuation Comparison 2026

TLSA

Biotechnology
Tiziana Life Sciences Ltd
Quality
1.7
out of 10
Value Trap
Price
$1.46
Last close
Models
7/13
Active
VS

TPST

Biotechnology
Tempest Therapeutics, Inc.
Quality
3.2
out of 10
Value Trap
36
LOW
Price
$1.73
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType TLSA Fair ValueTLSA Upside TPST Fair ValueTPST Upside
Bayesian DCF Intrinsic $0.39 -73.5% $0.32 -81.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.04 -97.4% $5.58 +222.6%
PWERM Option-Based $1.41 -3.8% $1.92 +11.3%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for TLSA vs TPST — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TLSA vs TPST — Which Stock Is More Undervalued?

TPST scores higher with a 3.2/10 quality rating vs TLSA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Tiziana Life Sciences Ltd (TLSA) and Tempest Therapeutics, Inc. (TPST) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TLSA currently trades at $1.46 with a QOC of 1.7/10, while TPST trades at $1.73 with a QOC of 3.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).